Emergent BioSolutions Stock

Emergent BioSolutions Quick Ratio

The Quick Ratio (Acid Test) of Emergent BioSolutions (EBS) as of Aug 10, 2026 is 1.78. In the previous year, Quick Ratio (Acid Test) was 1.20 — a change of 47.91% (higher).

Quick Ratio

1.78

YoY

47.91%

Last updated:

Quick Ratio (Acid Test) of Emergent BioSolutions is 2026 1.78 . Quick Ratio (Acid Test) of Emergent BioSolutions was 2025 1.20 . It decreases by 47.91% higher compared to the previous year.
Access this data via the Eulerpool API

Emergent BioSolutions Stock analysis

What does Emergent BioSolutions do? Emergent BioSolutions Inc is a biotechnology company specializing in the development of products for protection against biological threats, infectious diseases, and cancer. The company was founded in 1998 and is headquartered in Gaithersburg, Maryland, USA. Emergent BioSolutions' business model is based on developing and marketing innovative products for the protection of public health and national security. The company aims to respond to known and unknown threats and focus on the changing healthcare needs of society. Emergent BioSolutions operates in four business segments: Biosavérica, Vaccines, Therapeutics, and Contract Manufacturing. Biosavérica is a Latin American subsidiary specializing in the distribution of biological products in Central and South America. Vaccines develops and produces vaccines for infectious diseases such as anthrax, cholera, and typhoid. Therapeutics focuses on the development of anti-infectives and cancer therapeutics. Contract Manufacturing offers services to the biopharmaceutical industry, including the manufacturing, development, and analysis of biopharmaceutical products. Emergent BioSolutions' products include vaccines, antitoxins, antibodies, and therapeutics. One of their most well-known products is BioThrax, an anthrax vaccine used by the US government for defense against biological threats since 2002. Other products include the cholera vaccine Vaxchora, the flu medication FluBlok, and the antibody Anthim used for anthrax. Emergent BioSolutions has partnerships with various governments and organizations worldwide, including the US government, the European Commission, and the World Health Organization. This collaboration aims to ensure that Emergent BioSolutions provides products and services in the areas of national security and public health and enables a rapid response in the event of epidemics and pandemics. In recent years, Emergent BioSolutions has also made several acquisitions to strengthen its business. In 2017, they acquired Cangene Corporation, a company specialized in the manufacture of anti-infectives and antitoxins. In 2019, Emergent BioSolutions acquired PaxVax, a company developing vaccines for infectious diseases, and Adapt Pharma, a company specializing in antidotes for opioid overdose. Emergent BioSolutions is a company focused on innovative research and development, offering products for the protection of public health and national security. The company has experienced significant growth in recent years and strives to adapt to the changing healthcare needs of society. Emergent BioSolutions is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Emergent BioSolutions stock

Quick Ratio (Acid Test) of Emergent BioSolutions is 1.78 in 2026.

Quick Ratio (Acid Test) of Emergent BioSolutions changed from 1.20 to 1.78, representing a 47.91% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Quick Ratio (Acid Test) Emergent BioSolutions since 2006 – with annual values, charts, and detailed analysis.

The Quick Ratio measures liquidity by comparing liquid assets to current liabilities, excluding inventory. It is a more conservative measure than the current ratio.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Quick Ratio (Acid Test)'s Emergent BioSolutions with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

Leverage — Emergent BioSolutions

All Key Metrics — Emergent BioSolutions